Medtronic: Why the MiniMed Split Has Smart Money Watching
Strong stock · S&P 500 · Medtronic plc. (MDT) · Analysis as of 2026-10-30
Medtronic has just completed one of the biggest portfolio overhauls in its history, and its shares are holding firm. Does a leaner, faster-growing device maker deserve a closer look? Here is what the fundamentals and the price action are saying.
What happens when a $96 medical device giant sheds a business it spent years nurturing? In Medtronic's case, the market appears to be rewarding the clarity.
A Cleaner Story, Finally
Medtronic has completed the separation of MiniMed Group, its diabetes business, after the exchange offer's final results were announced. The move simplifies the portfolio. What remains is concentrated in higher-growth areas: cardiac ablation, structural heart, neuromodulation, surgical robotics and neurosurgery. Management no longer has to balance a different competitive and margin profile in diabetes. That focus is a large part of why sentiment has improved.
Pulsed Field Ablation: The Growth Engine
The most compelling product narrative sits in electrophysiology. Medtronic recently presented positive real-world registry results for its Sphere-9 catheter and PulseSelect PFA system. Real-world data matters because it shows that trial performance carries over to everyday clinical practice, and that is what drives hospital adoption. Medtronic's Stealth AXiS surgical system was also named to TIME's Best Inventions list. That recognition is anecdotal, but it supports the view that the innovation pipeline is delivering.
Valuation: Premium, But Not Stretched
| Metric | Value | |---|---| | Close Price | $96.54 | | P/E Ratio | 23.72 | | PEG Ratio | 1.74 | | Sector | Healthcare / Medical Devices |
A P/E of 23.72 is a reasonable multiple for a company with Medtronic's scale, recurring procedure-driven revenue and long record of dividend growth. The PEG of 1.74 shows investors are paying a moderate premium for expected earnings growth rather than an extreme one. If PFA and robotics lift growth as the company anticipates, that multiple becomes easier to justify. The risk is execution. Competitors in ablation and robotics are well funded, and growth must keep accelerating for the premium to hold.
Sector Backdrop
Medical devices tend to be defensive. Procedure volumes are supported by ageing demographics and the backlog of elective care. Tariffs and supply-chain costs remain a watch item for the industry, but Medtronic's global manufacturing footprint and scale give it more flexibility than smaller peers.
What the Charts Are Telling Us
Price action reflects the improving narrative. Shares have held a constructive structure near the mid-$90s, with pullbacks drawing steady interest rather than heavy distribution. Momentum indicators such as RSI and MACD are broadly positive without flashing extreme overbought readings, which suggests room to extend rather than a stretched move. Traders typically watch whether the shares can keep holding above rising short- and medium-term moving averages. A sustained hold would confirm that the trend has institutional backing. A slip back below those averages would be the first sign that enthusiasm is fading.
Key Levels and Risks
- Supportive: portfolio simplification, PFA momentum, defensive sector, steady dividend profile
- Watch: competitive pressure in ablation and robotics, tariff exposure, post-separation execution
The Takeaway
Medtronic is changing from a sprawling conglomerate into a focused growth story, and the technical picture is consistent with that shift. At 23.72 times earnings, the market is giving credit for the transition. It has not yet priced in perfection. The next few quarters of PFA and robotics results will show whether the strength is durable.
--- Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.